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The Editorial on the Research Topic
Molecular Function and Regulation of Non-coding RNAs in Multifactorial Diseases
Most of the parts in the human genomic DNA do not produce any proteins. They encode functional
RNA molecules, which are not translated, and are thus named as non-coding RNAs (ncRNAs;
Cammaerts et al.; Hajjari et al., 2014). Depending on the length and the function of these RNAs,
they are categorized into different types such as microRNAs (miRNAs) and long non-coding
RNAs (lncRNAs). Different studies have shown that these RNAs have crucial roles in cellular
and molecular mechanisms. Considering their function, it is believed that the dysregulation of
ncRNAs is involved in different diseases, especially such complex ones as cancers, neurological
disorders, and cardiovascular diseases (Nouraee and Mowla; Merelo et al.; Hajjari et al., 2014).
Accordingly, some researchers believe that these molecules can help with the diagnosis and the
treatment of complex diseases. However, we have still a limited understanding of the functions of
these molecules, and the different aspects of ncRNAs are still to be discovered in future. The above
consideration was the motivation for the production of the topic entitled “Molecular function and
regulation of non-coding RNAs in multi-factorial diseases.”We believe that the articles in this issue
and the attributed e-book can provide the interesting viewpoints for the researchers interested in
this topic.
miRNAs are small RNAs with about 20–24 nucleotides length and function in post
transcriptional regulation of gene expression. They usually destabilize and repress target RNAs
via binding to 3′UTRs, 5′UTRs or the coding sequences of the transcripts (Lytle et al., 2007;
Qin et al., 2010). miRNAs have been demonstrated to play major roles in a wide range of
developmental processes as well as diseases. To understand the role of miRNA pathogenesis in
different diseases such as cancers, two different strategies including the expression analysis and
the genetic approaches are proposed (Reviewed in Cammaerts et al.). As such, the miRNAs are
currently considered as new potential biomarkers for different diseases (Angelini and Emanueli).
Furthermore, some reports have interestingly shown the plasma and saliva miRNAs as potentially
sensitive and specific biomarkers (Lin et al.; Khoo et al., 2012). Nonetheless, there are still some
concerns with the functionality of miRNAs that need to be addressed in future.
By modulating different targets or pathways, miRNAs have been quickly considered as
potential therapeutic molecules for some diseases such as cancer (reviewed in Naidu et al., 2015)
and cardiovascular ones (Nouraee and Mowla). miRNA-based therapeutics mainly focuses on
modulation of the miRNA expression levels (Misso et al., 2014). MRX34, an agent mimicking
miR-34 and developed by Mirna Therapeutics, has progressed into phase I clinical trials (identifier:
19 February 2016
Hajjari et al. ncRNAs in Complex Diseases
NCT01829971, Currently recruiting participants, Estimated
study completion date: Dec 2016). The results may hopefully
provide more insights for the researchers. In spite of different
researches, there are still some challenges in designing a
suitable carrier for targeting miRNAs into the desired cells.
Bakhshinejad reports the studies proposing the nanocarriers as
the potential tools to overcome delivery problems concerned with
miRNA-based pharmaceutical tools (Bakhshinejad).
lncRNAs, the RNAs longer that 200 nucleotides, comprise the
largest proportion of the human transcriptome. The biology of
lncRNAs seems more complicated in comparison to miRNAs.
These RNAs act through more different pathways and modes
of action within the cell. They function at transcriptional and
post-transcriptional levels, in the cytosol and nucleus through cis
and trans-regulatory mechanisms (Hajjari et al., 2014; Angrand
et al.). Different lncRNAs such as HOTAIR, H19, MEG3, ANRIL,
HULC, and XIST are transcribed within the genome and play
important roles in different cellular pathways (reviewed inHajjari
et al., 2014). Multiple lines of observation increasingly associate
the mutations and the dysregulations of lncRNAs to some human
diseases such as cancer (reviewed in Angrand et al.; Hajjari
et al., 2014). On the current subject matter, Shahryari et al. have
provided some evidence showing that some lncRNAs such as
SOX2OT are also involved in pluoripotency (Shahryari et al.).
Peschanscky et al. have also described the novel facets of FMR4
lncRNA functionality and its relation to neurodevelopment
(Peschansky et al.).
The growing evidence of the dysregulated lncRNAs not only
introduces a new layer of complexity in themolecularmechanism
of human diseases, but also opens up the opportunity to use
lncRNAs as therapeutic targets and biomarkers. The prominent
example of lncRNAs application in clinical practices is PCA3
(Prostate cancer gene 3), an FDA-approved biomarker for the
prostate cancer. According to this test, the PSA and PCA3
RNA molecules are measured, and then the PCA3 Score (a
ratio of PCA3 RNA to PSA RNA) is calculated (http://www.fda.
gov). Circulating lncRNAs have been also suggested as potential
biomarkers for cancer and some other diseases. Exomal lncRNAs
have been suggested as potential biomarkers to diagnose the
malignant state of patients with prostate cancer (Is¸in et al.).
The rapidly growing list of ncRNAs holds promises that
miRNAs and lncRNAswill become evermore important in illness
management in future. The elucidation of the mechanisms by
which lncRNAs act will help us to design suitable biomarkers
or therapeutic agents for some diseases, especially cancer. The
deciphering of the genetic networks and pathways regulated
by the abnormally expressing lncRNAs, the characterization of
miRNA-mRNA-lncRNA interaction, and the genetic/epigenetic
mechanisms regulating the lncRNA expression provide more
insights into the application of lncRNA research to human
health. Considering the different molecular functions of ncRNAs,
these RNAs can be the subject of a large diversity of further
studies on complex diseases. We trust that the publications and
the novelties on this subject will be exponentially extended in
future.
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